Literature DB >> 15806434

Immunotherapy in metastatic renal cell carcinoma.

Karl Rohrmann1, Michael Staehler, Nikolas Haseke, Alexander Bachmann, Christian G Stief, Michael Siebels.   

Abstract

Metastatic renal cell carcinoma has a poor prognosis. Conventional therapies such as chemotherapy, radiation or hormonal treatment have hardly any effect on the progression of this disease. As renal cell carcinoma seems to be an immunogenic tumor, several immunotherapeutic approaches with different response rates have been developed since the early 1990s. We present an overview of various immunotherapeutic approaches such as cytokine-based regimes, with and without different cytotoxic chemotherapy, of metastatic renal cell carcinoma. In addition, local therapies (e.g. inhalation of interleukin-2) are reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806434     DOI: 10.1007/s00345-004-0470-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  57 in total

1.  Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.

Authors:  W M Stadler; T Kuzel; M Dumas; N J Vogelzang
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

2.  Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.

Authors:  C W Ryan; N J Vogelzang; M C Dumas; T Kuzel; W M Stadler
Journal:  Cancer       Date:  2000-03-15       Impact factor: 6.860

Review 3.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

4.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

5.  Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.

Authors:  J A Ellerhorst; A Sella; R J Amato; S M Tu; R E Millikan; L D Finn; M Banks; C J Logothetis
Journal:  Cancer       Date:  1997-12-01       Impact factor: 6.860

6.  Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.

Authors:  G Hofmockel; W Langer; M Theiss; A Gruss; H G Frohmüller
Journal:  J Urol       Date:  1996-07       Impact factor: 7.450

7.  Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.

Authors:  M Volm; M Kästel; J Mattern; T Efferth
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

Review 8.  [Regional immunotherapy of metastatic renal cell carcinoma].

Authors:  H Heinzer; E Huland; H Huland
Journal:  Urologe A       Date:  2002-05       Impact factor: 0.639

9.  Prognostic significance of incidental renal cell carcinoma.

Authors:  D Bretheau; E Lechevallier; C Eghazarian; V Grisoni; C Coulange
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

10.  Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Authors:  J Atzpodien; H Kirchner; U Jonas; L Bergmann; H Schott; H Heynemann; P Fornara; S A Loening; J Roigas; S C Müller; H Bodenstein; S Pomer; B Metzner; U Rebmann; R Oberneder; M Siebels; T Wandert; T Puchberger; M Reitz
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

View more
  13 in total

1.  The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.

Authors:  Agnès Maillet; Laurent Guilleminault; Etienne Lemarié; Stéphanie Lerondel; Nicolas Azzopardi; Jérôme Montharu; Nicolas Congy-Jolivet; Pascale Reverdiau; Brigitte Legrain; Christelle Parent; Dominique-Henri Douvin; José Hureaux; Yves Courty; Michèle De Monte; Patrice Diot; Gilles Paintaud; Alain Le Pape; Hervé Watier; Nathalie Heuzé-Vourc'h
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

2.  Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.

Authors:  Bruce A Feinberg; Pradeep Jolly; Si-Tien Wang; Barry Fortner; Jeffrey Scott; James Gilmore; Maureen P Neary; Mei Sheng Duh
Journal:  Med Oncol       Date:  2011-04-09       Impact factor: 3.064

Review 3.  Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.

Authors:  I Duran; J Lambea; P Maroto; J L González-Larriba; Luis Flores; S Granados-Principal; M Graupera; B Sáez; A Vivancos; O Casanovas
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

Review 4.  Update on systemic therapies of metastatic renal cell carcinoma.

Authors:  E Herrmann; S Bierer; C Wülfing
Journal:  World J Urol       Date:  2010-02-24       Impact factor: 4.226

5.  [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].

Authors:  M Siebels; A Hegele; Z Varga; R Oberneder; C Doehn; H Heinzer
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

6.  Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; Andrew Gannon; Robert A Figlin
Journal:  Oncologist       Date:  2016-11-02

7.  Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.

Authors:  Jakub Zołnierek; Pawel Nurzyński; Przemysław Langiewicz; Sylwia Oborska; Anna Waśko-Grabowska; Ewa Kuszatal; Beata Obrocka; Cezary Szczylik
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-27       Impact factor: 4.553

8.  YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway.

Authors:  S Y Wu; S L Pan; T H Chen; C H Liao; D Y Huang; J H Guh; Y L Chang; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  2008-07-21       Impact factor: 8.739

9.  Physalin F induces cell apoptosis in human renal carcinoma cells by targeting NF-kappaB and generating reactive oxygen species.

Authors:  Szu-Ying Wu; Yann-Lii Leu; Ya-Ling Chang; Tian-Shung Wu; Ping-Chung Kuo; Yu-Ren Liao; Che-Ming Teng; Shiow-Lin Pan
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

Review 10.  Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

Authors:  Nathalie Theou-Anton; Sandrine Faivre; Chantal Dreyer; Eric Raymond
Journal:  Drug Saf       Date:  2009       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.